Clofarabine and Cytarabine Combination in Patients with Fludarabine/Cytarabine Refractory Acute Myeloid Leukemia

The long-term outcome of patients with relapsed/refractory acute myeloid leukemia (R/R-AML) is dismal and allogeneic hematopoietic cell transplantation (allo-HCT) seems to be the only curative treatment option for these patients. Patients who undergo allo-HCT in complete remission (CR) do benefit most from the procedure. Clofarabine in combination with cytarabine (CLARA) is an effective regimen in AML patients both in frontline and R/R settings. Here we report our multicenter, retrospective experience with CLARA in patients with fludarabine/cytarabine (FLA) refractory AML.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Emre Tekg ündüz, Ali Kaya, Sinem Bozdağ, Mehmet Doğu, Mehmet Dal, Filiz Bekdemir, Merih Kızıl, Hakan Sarı, Fevzi Altuntas Source Type: research